Zevra Therapeutics Aktie News

Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed

BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, announced today that its Chief Medical Officer (“CMO”) Adrian Quartel, M.D., FFPM, will be stepping down from his position due to personal reasons, effective July 3, 2026. Dr. Q...

Zevra Therapeutics (NASDAQ:ZVRA) said it has submitted a patent covering its product MIPLYFFA for listing in the US Food and Drug Administration's Orange Book, with patent protection extending to 2041. The submission seeks to list the patent in the Orange Book, the FDA's register of approved drug products and the patents associated with them, the company said.

MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases...

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 33,000 shares of the Company's common stock (the “Inducement Awards”) to four new employees pursu...